Changes in Beneficial Ownership · 4
ZAI LAB LTD
ZAILFOTCEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- Zai Lab Ltd
- Issuer CIK
- 0001704292
- Trading symbol
- ZLAB
Reporting owner 1
- Name
- Chen Yajing
- Reporting owner CIK
- 0001985694
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| American Depositary Shares[F1] | 2026-08-14 | M · Form 4 | 1,250[F2] | A | [F3] | 36,322 | D |
| American Depositary Shares[F1] | 2026-08-14 | F · Form 4 | 427[F4] | D | 25.9 | 35,895 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share Units | [F3] | 2026-08-14 | M · Form 4 | 1,250 | D | 0 | [F5] | [F5] | American Depositary Shares[F1] | 1,250 | 1,250 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.↩ 1↩ 2↩ 3
- F2
- ADSs acquired upon vesting of Restricted Share Units ("RSUs").↩ 1
- F4
- These ADSs were withheld to cover taxes upon vesting of RSUs.↩ 1
Signature 1
- Signed
- /s/ Bruce Blefeld, Attorney-in-Fact
- Date
- 2026-08-18
Company context
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.